|本期目录/Table of Contents|

[1]王 勇,陈雅婧 综述,岳 丹审校.YB-1对肿瘤增殖调控的研究进展[J].天津医科大学学报,2014,20(04):332-334.
点击复制

YB-1对肿瘤增殖调控的研究进展(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
20
期数:
2014年04期
页码:
332-334
栏目:
综述
出版日期:
2014-07-08

文章信息/Info

Title:
-
文章编号:
1006-8147(2014)04-0332-03
作者:
王 勇1陈雅婧2 综述岳 丹2审校
(1. 天津医科大学第二医院泌尿外科,天津市泌尿外科研究所,天津 300211;2. 天津医科大学医学检验学院,天津 300203)
Author(s):
-
关键词:
YB-1肿瘤增殖
Keywords:
-
分类号:
R730
DOI:
-
文献标志码:
A
摘要:
-
Abstract:
-

参考文献/References:

[1] Maciejczyk A, Szelachowska J, Ekiert M, et al. Elevated nuclear YB1 expression is associated with poor survival of patients with early breast Cancer[J]. Anticancer Res, 2012,32(8):3177

[2]Chatterjee M, Rancso C, Stühmer T, et al.The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma[J]. Blood,2008,111(7):3714

[3]Lasham A, Moloney S, Hale T, et al.The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor[J]. J Biol Chem,2003,278(37):35516

[4]Lasham A, Samuel W, Cao H, et al.YB-1, the E2F pathway, and regulation of tumor cell growth[J]. J Natl Cancer Inst,2012,104(2):133

[5]Rhodes D R, Kalyana-Sundaram S, Mahavisno V, et al. Mining for regulatory programs in the cancer transcriptome[J]. Nat Genet,2005,37(6):579

[6]Finkbeiner M R,Astanehe A,To K, et al.Profiling YB-1 target genes uncovers a new mechanism for Met receptor regulation in normal and malignant human mammary cells[J].Oncogene,2009,28(11):1421.

[7]Jürchott K, Kuban R J, Krech T, et al. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal Cancer cells[J].PLoS Genet,2010,6(12):e1001231

[8]Basaki Y,Hosoi F,Oda Y, et al.Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian Cancer cells[J].Oncogene,2007,26(19):2736.

[9]Cornu M,Albert V, Hall M N.mTOR in aging,metabolism,and Cancer[J].Curr Opin Genet Dev,2013,23(1):53

[10]Astanehe A,Finkbeiner M R,Hojabrpour P, et al.The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1[J].Oncogene,2009,28(25):2406

[11]Sutherland B W,Kucab J,Wu J, et al.Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast Cancer cells[J].Oncogene,2005,24(26):4281

[12]Sinnberg T,Sauer B,Holm P, et al.MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop[J].Exp Dermatol,2012,21(4):265

[13]Schittek B,Psenner K,Sauer B, et al.The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance[J].Int J Cancer,2007,120(10):2110

[14]Fujii T,Seki N,Namoto-Matsubayashi R, et al.YB-1 prevents apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast Cancer cells[J].Future Oncol,2009,5(2):153

[15]De Luca A,Maiello M R,D’alessio A, et al.The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in Cancer pathogenesis and implications for therapeutic approaches[J].Expert Opin Ther Targets,2012,16(Suppl 2):S17

[16]Aksamitiene E,Kiyatkin A,Kholodenko B N.Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance[J].Biochem Soc Trans,2012,40(1):139

[17]Wu J,Lee C,Yokom D, et al.Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2[J].Cancer Res,2006,66(9):4872

[18]Moncho-Amor V,Ibañez de Cáceres I,Bandres E, et al.DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung Cancer[J].Oncogene,2011,30(6):668

[19]Coles L S,Lambrusco L,Burrows J, et al.Phosphorylation of cold shock domain/Y-box proteins by ERK2 and GSK3beta and repression of the human VEGF promoter[J].FEBS Lett,2005,579(24):5372

[20]van Roeyen C R,Eitner F,Martinkus S, et al.Y-box protein 1 mediates PDGF-B effects in mesangioproliferative glomerular disease[J].J Am Soc Nephrol,2005,16(10):2985

相似文献/References:

[1]孙亚军,傅正,朱志峰,等.基因芯片分析三肽化合物酪丝亮肽对人肝癌基因表达谱的影响[J].天津医科大学学报,2013,19(05):353.
[2]叶剑飞 综述. microRNAs与肿瘤研究的新进展[J].天津医科大学学报,2014,20(05):416.
[3]孙秀梅,张 飞 综 述,牛瑞芳 审校. Nanog及其假基因NanogP8在肿瘤中的研究进展[J].天津医科大学学报,2015,21(03):90.
[4]孙秀梅,张 飞 综 述,牛瑞芳 审校. Nanog及其假基因NanogP8在肿瘤中的研究进展[J].天津医科大学学报,2015,21(01):90.
[5]黄 纯 综述,李 凯 审校. 肿瘤免疫治疗与化疗的协同效应研究现状[J].天津医科大学学报,2015,21(04):363.
[6]孔令平,周 旋 综述,张 仑 审校.长链非编码RNA MALAT1在肿瘤中的研究进展[J].天津医科大学学报,2015,21(04):367.
[7]郭小凡 综述,邓靖宇,梁 寒 审校.PCDH10启动子甲基化与恶性肿瘤关系的研究进展[J].天津医科大学学报,2016,22(02):182.

备注/Memo

备注/Memo:

基金项目 国家自然科学基金青年基金资助项目(81202380),天津市应用基础与前沿技术研究计划青年基金项目(12JCQNJC07800),教育部博士点基金资助项目(20111202120016),天津医科大学科研基金(2013KYQ04)

作者简介 王勇(1981-),男,讲师,博士,研究方向:泌尿系统肿瘤; 通信作者:岳丹,E-mail:danyue0705@sina.cn

更新日期/Last Update: 2014-06-06